257 related articles for article (PubMed ID: 28579282)
1. A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset.
Jang BS; Kim IA
Radiother Oncol; 2017 Sep; 124(3):403-410. PubMed ID: 28579282
[TBL] [Abstract][Full Text] [Related]
2. A radiosensitivity gene signature and PD-L1 predict the clinical outcomes of patients with lower grade glioma in TCGA.
Jang BS; Kim IA
Radiother Oncol; 2018 Aug; 128(2):245-253. PubMed ID: 29784449
[TBL] [Abstract][Full Text] [Related]
3. A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset.
Jang BS; Kim IA
Cancer Res Treat; 2020 Apr; 52(2):530-542. PubMed ID: 31801317
[TBL] [Abstract][Full Text] [Related]
4. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
Jang BS; Han W; Kim IA
Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471
[TBL] [Abstract][Full Text] [Related]
5. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
6. PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection.
Lyu X; Zhang M; Li G; Jiang Y; Qiao Q
J Cancer; 2019; 10(4):937-948. PubMed ID: 30854100
[No Abstract] [Full Text] [Related]
7. Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on The Cancer Genome Atlas Dataset.
Dai D; Guo Y; Shui Y; Li J; Jiang B; Wei Q
Front Mol Biosci; 2021; 8():775562. PubMed ID: 34970597
[No Abstract] [Full Text] [Related]
8. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
9. Genomic stratification based on radiosensitivity and PD-L1 for tailoring therapeutic strategies in cervical cancer.
Lyu X; Jiang Y; Zhang M; Li G; Li G; Qiao Q
Epigenomics; 2019 Jul; 11(9):1075-1088. PubMed ID: 31179743
[No Abstract] [Full Text] [Related]
10. Validation of a radiosensitivity molecular signature in breast cancer.
Eschrich SA; Fulp WJ; Pawitan Y; Foekens JA; Smid M; Martens JW; Echevarria M; Kamath V; Lee JH; Harris EE; Bergh J; Torres-Roca JF
Clin Cancer Res; 2012 Sep; 18(18):5134-43. PubMed ID: 22832933
[TBL] [Abstract][Full Text] [Related]
11. Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy.
Shen J; Liu J; Li H; Bai L; Du Z; Geng R; Cao J; Sun P; Tang Z
Radiat Oncol; 2021 Nov; 16(1):223. PubMed ID: 34794456
[TBL] [Abstract][Full Text] [Related]
12. The Expression Level of
Masuda T; Noda M; Kitagawa A; Hu Q; Fujii A; Ito S; Kosai K; Ando Y; Matsumoto Y; Ohtsu H; Uchida H; Ohno S; Mimori K
Anticancer Res; 2020 Jul; 40(7):3733-3742. PubMed ID: 32620612
[TBL] [Abstract][Full Text] [Related]
13. Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.
Higgs BW; Morehouse CA; Streicher K; Brohawn PZ; Pilataxi F; Gupta A; Ranade K
Clin Cancer Res; 2018 Aug; 24(16):3857-3866. PubMed ID: 29716923
[No Abstract] [Full Text] [Related]
14. Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.
Sjöström M; Staaf J; Edén P; Wärnberg F; Bergh J; Malmström P; Fernö M; Niméus E; Fredriksson I
Breast Cancer Res; 2018 Jul; 20(1):64. PubMed ID: 29973242
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
Budczies J; Bockmayr M; Denkert C; Klauschen F; Gröschel S; Darb-Esfahani S; Pfarr N; Leichsenring J; Onozato ML; Lennerz JK; Dietel M; Fröhling S; Schirmacher P; Iafrate AJ; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2016 Aug; 55(8):626-39. PubMed ID: 27106868
[TBL] [Abstract][Full Text] [Related]
16. A novel PD-1/PD-L1 pathway-related seven-gene signature for the development and validation of the prognosis prediction model for breast cancer.
Zhang P; Yang J; Zhong X; Selistre-de-Araujo HS; Boussios S; Ma Y; Fang H
Transl Cancer Res; 2024 Mar; 13(3):1554-1566. PubMed ID: 38617520
[TBL] [Abstract][Full Text] [Related]
17. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
Brüggemann C; Kirchberger MC; Goldinger SM; Weide B; Konrad A; Erdmann M; Schadendorf D; Croner RS; Krähenbühl L; Kähler KC; Hafner C; Leisgang W; Kiesewetter F; Dummer R; Schuler G; Stürzl M; Heinzerling L
J Cancer Res Clin Oncol; 2017 Oct; 143(10):1977-1984. PubMed ID: 28616701
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer.
Vidula N; Yau C; Rugo HS
Breast Cancer Res Treat; 2021 Jun; 187(2):387-395. PubMed ID: 33913053
[TBL] [Abstract][Full Text] [Related]
20. Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer.
Torres-Roca JF; Fulp WJ; Caudell JJ; Servant N; Bollet MA; van de Vijver M; Naghavi AO; Harris EE; Eschrich SA
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):631-8. PubMed ID: 26461005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
